CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- Open-market buys, last 90 days
- $2,743,765
- in 2 filings
- Open-market sales, last 90 days
- $1,708,041
- in 8 filings, $650K under 10b5-1 plans
Net +$1,035,724. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- WILSON TROY EDWARD +$2.7M President and CEO 2 filings
- Bair Teresa Brophy −$486K Chief Legal Officer sold 18% of stake
- Leoni Mollie −$440K Chief Medical Officer sold 23% of stake
- Powl Brian T. −$397K Chief Commercial Officer sold 21% of stake
- Burrows Francis −$225K Chief Scientific Officer sold 33% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-28 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −4,607 | $10.50 | $48K | 142,428 |
| 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −2,226 | $8.46 | $19K | 150,083 |
| 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −1,114 | $8.46 | $9K | 148,969 |
| 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −695 | $8.46 | $6K | 148,274 |
| 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −2,226 | $8.46 | $19K | 146,048 |
| 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −881 | $8.46 | $7K | 145,167 |
| 2026-01-02 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award | +21,250 | 152,309 | ||
| 2026-01-02 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award · Option to purchase common stock | +42,500 | 42,500 | ||
| 2025-11-14 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −4,539 | $11.18 | $51K | 130,257 |
| 2025-11-13 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award | +24,967 | 134,796 | ||
| 2025-09-29 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −4,541 | $8.94 | $41K | 109,829 |
| 2025-09-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award | +24,966 | 114,370 | ||
| 2025-01-28 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −2,241 | $7.87 | $18K | 90,901 |
| 2025-01-28 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −887 | $7.87 | $7K | 90,014 |
| 2025-01-28 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −699 | $7.87 | $6K | 89,315 |
| 2025-01-28 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −1,122 | $7.87 | $9K | 88,193 |
| 2025-01-02 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award | +21,250 | 71,892 | ||
| 2025-01-02 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award | +21,250 | 93,142 | ||
| 2025-01-02 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Grant or award · Option to purchase common stock | +42,500 | 42,500 | ||
| 2024-01-29 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | −594 | $17.80 | $11K | 49,817 |
Page 1 of 2 · 24 trades